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Abstract: Human Immunodeficiency Virus Type 1 (HIV-1) is the etiological agent of 
acquired immunodeficiency syndrome (AIDS), which affects over 34 million people 
worldwide. In sub-Saharan Africa where access to antiretroviral therapies (ART) is 
limited, mother-to-child transmission (MTCT) rates remain high and represent a major 
concern in the global HIV/AIDS epidemic. Little is known about the biological properties 
of viruses that are transmitted perinatally, including how the biological functions of 
envelope (Env) influence transmissibility. Previously, transmitted viruses were found to 
have an advantage in replicative fitness mediated by Env V1-V5. In this study viruses 
derived from transmitting mother infant pairs (MIPs) were used to determine if the 
binding and fusion activities are influenced by Env V1-V5 and if any differences 
correlate to replicative fitness and transmission. Fusion and binding assays were used to 
measure the biological functions of Env from individual clones of five MIP. RESULTS: 
Neither binding nor fusion is predictive of transmission. However, clonal variation in 
both functions is observed, demonstrating V1-V5 is capable of influencing fusion and 
binding. Fusion correlates with infectivity, but does not correlate with binding. The 
results of this study have provided new insights to better understand the functional 
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Chapter 1: Literature Review 
 
Overview of HIV-1 and the Global AIDS epidemic 
 Human immunodeficiency virus (HIV) is the etiological agent of acquired 
immunodeficiency syndrome (AIDS). The United Nations Program on AIDS (UNAIDS) 
estimated that as of 2010 there were 34 million people living with AIDS. Due to 
successes in increasing access to antiretroviral therapies (ART) worldwide, both the 
number of new HIV infections and AIDS-related deaths have decreased over the last 
decade. Another success has been an increase in access to HIV testing and counseling. 
However, testing in low- and middle-income countries still remains problematic. Women 
and children remain under-served in terms of testing and access to ART. Women also 
remain more affected by HIV than men in sub-Saharan Africa. Several other populations, 
for example men who have sex with men, remain also underserved. Low- and middle-
income countries with HIV/AIDS epidemics have made progress in increasing the 
availability of ART, but ultimately remain insufficient. Moving forward in the effort to 
combat the global HIV/AIDS epidemic, early detection of infection and early access to 
ART remained vital [WHO, 2011]. HIV-1 is a lentivirus within the retroviridae family. 
The HIV-1 genome has three major genes (gag, pol, and env) and a number of accessory 
genes. HIV-1 infects primarily CD4+ T cells and monocyte/macrophage lineage cells. 
Viral entry into host cells is initiated by the engagement of the receptor, CD4, and the 
coreceptor, CCR5 or CXCR4, by the envelope glycoprotein (Env) spike, a heterotrimer 
of three glycoprotein 120 molecules (gp120) bound to three transmembrane glycoprotein 
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41s (gp41). Following the binding events a conformational change induces fusion of the 
viral and cellular membranes that allows the HIV-1 core to be delivered to the cytoplasm. 
Once in the cytosol, the viral RNA is reverse transcribed into double-stranded DNA. The 
viral DNA is translocated into the nucleus and integrated into the host cell chromosomal 
DNA. This integrated DNA drives the transcription of viral RNA which is then 
transported to the cytoplasm to be translated. Newly synthesized viral proteins and two 
copies of the full length genomic RNA are assembled into new viral particles. As these 
particles are released, cleavage of the viral protein into the mature form takes place to 
generate the mature virions capable of initiating new infection. 
 Transmission of HIV-1 occurs through sexual and non-sexual routes. Sexual 
transmission remains the major route of HIV-1 transmission in sub-Saharan Africa and 
globally [WHO, 2011]. Both heterosexual and homosexual transmission across mucosal 
epithelial cells is common.  Many factors contribute to the risk of sexual transmission 
including the disease status of the transmitting partner, the susceptibility of the recipient 
partner, the number exposures, the type of sexual act, and characteristics of the 
transmitted virus. Viral load of the index partner is a major risk factor in sexual 
transmission. Viral load in genital secretions is also a determinant during sexual 
transmission. Often viral levels in both the female genital tract and in semen correlate 
with plasma viral loads. Acute infection, late-stage disease, and other infections are all 
factors that can increase HIV-1 concentrations in the blood and are risk factors for sexual 
transmission. The presence of STIs or other conditions that are capable of disrupting the 
mucosal layer in the genital tract that leads to an increase in sexual transmission [Galvin 
and Cohen, 2004].  
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Mother to child transmission and the HIV/AIDS Epidemic 
 Another major route of HIV transmission is perinatal transmission. UNAIDS 
estimated in 2008 that there were over two million children living with HIV. 
Approximately 90% of these children were infected during pregnancy, birth, or through 
breastfeeding [Ahmad, 2000; UNAIDS, 2008]. Recent programs to prevent mother to 
child transmission (MTCT) as well as access to ART have achieved a measure of success 
at limiting new child infections of HIV and child deaths due to AIDS [WHO, 2011]. 
However, as of 2010 there were still 390,000 new HIV infections in children under 15, 
only 35% of pregnant women were tested for HIV, and 48% of HIV positive pregnant 
women were receiving some form of antiretroviral treatment. A majority of these new 
pediatric infections occurred in sub-Saharan Africa [WHO, 2011]. In countries with the 
highest HIV prevalence, it is the underlying cause of one-third of the deaths of children 
under the age of five [Bennnett and Rogers, 1991; WHO, 2011]. In many developing 
countries and in the absence of ART, perinatal transmission rates remain between 30-
45% [Bulterys and Lepage, 1998; Lathey et al, 1999]; this is of particular concern in sub-
Saharan Africa where access to ART is still limited and HIV-1 infection is epidemic 
[Cooper et al, 2002]. MTCT remains a major concern in the global fight against 
HIV/AIDS. 
Routes and risk factors for perinatal transmission 
 HIV perinatal transmission occurs through three routes; intrauterine, intrapartum, 
and during breast feeding. However, these routes are hard to distinguish and mechanisms 
underlying perinatal are not well-understood. It is likely that interplay between host and 
viral factors will play important roles in perinatal transmission. Maternal parameters that 
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could influence MTCT include advanced clinical stages of the disease, a low CD4+ 
lymphocyte count, a high level of circulating HIV-1, and disease progression. Also, 
maternal immune response to HIV-1 and recent infection have been implicated as risk 
factors for perinatal transmission [Adjorlolo-Johnson et al, 1994; Newell, 1995; Ryder et 
al, 1989; Study, 1994]. Studies indicate that an elevated viral load in the mother plays a 
role in MTCT [Cao et al, 1997; Garcia et al, 1999; Newell and Peckham, 1993]. Acute 
infection during pregnancy, the presence of sexually transmitted diseases or other chronic 
infections, and the disruption of placental integrity are also associated with perinatal 
transmission [Newell, 1993; Report, 1992]. Some studies provide evidence that vitamin 
A deficiency, malnutrition that lead to immunodeficiency, and disruption of mucosal 
integrity, are all associated with an increased risk of perinatal transmission of HIV-1 
[Semba, 1997].  
Intrauterine transmission 
 It is often difficult to distinguish between the routes of perinatal transmission; 
while some studies point to specific risk factors associated with each route, these results 
still remain controversial. A number of studies have shown that HIV is capable of 
infecting the placenta at all stages of pregnancy. HIV-1 has been isolated from aborted 
fetuses as early as 8 weeks of gestation, indicating that early in utero transmission also 
takes place [Lewis, 1990]; however, the risk of placental infection appears to be more 
likely during late pregnancy. Placental disruption, secondary to chorioamnionitis or 
smoking, has been associated with increased risk of transmission [Newell, 1995]. 
Generally, diagnosis of in utero infection involves HIV-1 that can be detected by virus 
culture or PCR in peripheral blood within 48 hours of birth [Lewis, 1990]. Intrauterine 
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transmission could also occur during late pregnancy, and HIV-1 may not be detectable in 
infant plasma for several days to a week after birth, and therefore a negative PCR test at 
birth cannot exclude in utero transmission [Dunn et al, 2000].  
Intrapartum transmission 
 Many factors important in intrauterine transmission can also increase the risk for 
intrapartum transmission. They include maternal plasma viral load, lack of antiretroviral 
use during pregnancy, and ascending infections from the vagina/cervix to fetal 
membranes and amniotic fluid [Newell, 1995]. HIV has been cultured from cellular and 
cell-free fractions of vaginal and endocervical secretions. There is some evidence that the 
excretion of HIV in these secretions is higher in pregnant women [UNAIDS, 2008], thus 
enhancing the risk of intrapartum transmission. Overall, intrapartum transmission rates 
range from ~10-20% and transmission during delivery accounts for ~2/3 of infant 
infections. Obstetrical considerations, including mode of delivery, may alter the duration 
of ruptured membranes and was shown to have an effect on the risk of HIV transmission 
[Newell and Peckham, 1993]. Unique risk factors influencing transmission during the 
intrapartum period include genital tract HIV-1 levels, genital ulcer disease, delivery 
complications, and breaks in the placental barrier. Another recently reported risk factor 
during delivery is placental microtransfusions, which were found to be associated with 
increased intrapartum but not in utero transmission [Kwiek et al, 2006].  
Transmission during breastfeeding 
 Infection via breastfeeding is difficult to determine closely following parturition, 
because it is hard to distinguish breast milk transmission from late intrauterine or 
intrapartum infections. It is estimated that as many as one-third to one-half of the infants 
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infected with HIV-1 were infected via breast milk [UNAIDS, 2008]. In countries where 
alternatives to breastfeeding are not available, overall transmission risk increases to 30-
45% [Rousseau et al, 2004; Thorne and Newell, 2003]. A meta-analysis of nine cohorts 
of HIV-1 infected breastfeeding mothers reported that infant infections attributable to 
breastfeeding during the first month following birth was 24~42% [Coutsoudis et al, 
2004]. Two of the most important determinants of breast milk transmission risk are 
duration of breastfeeding and HIV-1 viral levels in breast milk. In general, breast milk 
HIV-1 RNA concentrations are 2-3 log10 lower than levels in plasma, ranging from 
undetectable to greater than 105 log10 copies/ml, and are highly correlated with plasma 
HIV-1 viral load [Rousseau et al, 2004]. Local inflammation resulting from mastitis, 
breast abscess, or other pathology may increase breast milk virus levels and the risk of 
transmission [John et al, 2001]. It is still unclear if transmission occurs through HIV 
infected cells in breast milk or through cell-free HIV in breast milk. Chronic or acute 
maternal infection does not appear to play a role in the risk of transmitting the virus to 
offspring via breastfeeding [Newell, 1995]. 
Host genetic factors 
 Maternal and infant genetic factors also play a role in MTCT. Human leukocyte 
antigen (HLA) concordance between the mother and infant increases the risk of 
transmission [Mackelprang et al, 2008; Polycarpou et al, 2002]. Certain variations in 
HLA have been shown to be associated with MTCT. Mothers with certain HLA- B 
(1302, 3501, 3503, 4402, 5001) variants were shown to transmit to their children even 
with low viral loads. Mothers with HLA-B 4901 and 5301 showed a lower risk of 
transmission even with high viral loads [Winchester et al, 2004]. Another study found 
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that mother-infant pairs that were discordant for HLA-G variants 3743 C/T, 634 C/G, and 
714insG/G had a decreased risk for transmission [Aikhionbare et al, 2006].  
 The structure and function of CCR5 in both mothers and infants also influences 
MTCT. Modifications of CCR5, such as a 32-bp deletion from the coding region (∆32) 
provide protection from infection. Individuals homozygous for ∆32 have almost complete 
protection from infection. Some studies support protection from MTCT in heterozygous 
infants [Kostrikis et al, 1999], while others do not [Misrahi et al, 1998]. The chemokine 
CCL3 is a natural ligand for CCR5 and acts as a potent agonist against HIV-1. CCL3 
produced by both infants and mothers affects transmission. Infants that produce less 
CCL3 were more susceptible to HIV-1 infection than infants that were exposed to HIV-1 
and produced high amounts of CCL3. Similarly, mothers that produced less CCL3 were 
more likely to transmit [Meddows-Taylor et al, 2006]. 
 Up regulation of CCR5 in the placenta may be related to transmission. Behbahani 
et. al. [2000] found a four-fold increase in the ratio of CCR5:CXCR4 expression in the 
placenta from transmitting mothers compared to non-transmitting mothers. Studies 
carried out with a MTCT cohort from Malawi showed that polymorphisms in the CCR5 
gene were related to an increase in CCR5 expression in the placenta; however, they were 
unable to show that this increase in expression led to an increase in transmission [Joubert 
et al, 2010]. At low maternal viral loads, SNP in CCR5 (2459G and 2135T) were 
associated with lower CCR5 expression in the placenta and provided some protection 
against transmission [Pedersen et al, 2007]. 
HIV-1 Env synthesis, structure, and function  
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 While host genetic factors may contribute to perinatal transmission, there is also 
evidence that viral factors may play a key role. Env is important in both infection and 
transmission and is likely an important viral factor in perinatal transmission. An 
understanding of the structure, function, and genetic diversity of Env is important in 
determining its role in MTCT.  
The Env glycoproteins are synthesized as a precursor glycoprotein (gp160) on the 
rough endoplasmic reticulum (RER) [Hunter and Swanstrom, 1990; Freed et al, 1995]. 
While still on the ER, gp160 is modified by glycosylation with primarily N-linked 
oligosaccharide side chains. Oligorimerization of gp160 into trimers also occurs in the 
ER and is thought to facilitate trafficking to the Golgi complex. Further modification to 
the oligosaccharide side chains continues as gp160 traffics through the trans-Golgi 
network [Leonard 1990]. 
 Env gp160 is proteolytically cleaved by cellular proteases at a highly conserved 
K/R-X-K/RR motif in the Golgi [Freed et al, 1989]. This cleavage, which yields the 
surface subunit gp120 and the transmembrane subunit gp41, is essential for viral 
infectivity. Three molecules of gp120 and three molecules of gp41 form a heterotrimeric 
spike. Relatively weak noncovalent interactions maintain the association between gp120 
and gp41 [Zhu et al, 2003]. The spike proteins are trafficked to the plasma membrane. It 
is thought that two factors contribute to the low cell surface expression and virion 
incorporation of the Env proteins. First, Env is rapidly recycled via endocytosis from the 
PM [Egan et al, 1996; Rowell et al, 1995]. Second, the weak interactions between gp120 
and gp41 allow for shedding of gp120. The resultant low expression of the glycoproteins 




 Based on high genetic diversity, gp120 is organized into five variable regions 
(V1-V5) separated by five more constant regions (C1-C5) [Starcich et al, 1986; Willey et 
al, 1986]. Within these regions, the V1/V2 loop has the most diversity in length and 
glycosylation. The V3 loop as well as C2, C3, and C4 have the least variation in length. It 
is likely that variation in the loop length, particularly V1/V2, plays a role in immune 
evasion by masking antibody binding sites [Chohan et al, 2005; Kitrinos et al, 2003; 
Masciotra et al, 2002; Palmer et al, 1996; Sagar et al, 2006; Shioda et al, 1997]. The 
major role of gp120 is binding of the virion to the target cell. Both the CD4 and 
CCR5/CXCR4 binding sites are located within gp120. CD4 binding is determined by the 
tertiary structure, where discontinuous conserved residues found in C1, C3, and C4 are 
brought into proximity [Lasky et al, 1987; Kowalski et al, 1987; Olshevsky et al, 1987]. 
The coreceptor binding site is located in the V3 loop [Cann et al, 1992; Chesebro et al, 
1991; Hwang et al, 1991; O'Brien et al, 1990; Shioda et al, 1991]. Specific mutations 
within V3 facilitate the switch from CCR5 to CXCR4 usage [Fouchier et al, 1992; 
Pollakis et al, 2004]. V3 also plays a role in membrane fusion [Freed et al, 1991] and 
contains epitopes for neutralizing antibodies [Goudsmit et al, 1988; Matsushita et al, 
1988; Palker et al, 1988; Rusche et al, 1988]. Binding to CD4 produces a large number of 
conformational changes within the Env that exposes the R5/ X4 binding sites. Thus, the 
unbound form of Env is able to mask the vulnerable V3 region until coreceptor binding 
occurs [Chen et al, 2005]. 
 Tertiary structure is also highly influenced by glycosylation and a number of 
conserved Cysteine residues capable of forming disulfide bonds [Leonard et al, 1990]. 
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The gp120 is primarily modified with N-linked glycans [Allan et al, 1985] with a smaller 
number of O-linked glycans [Bernstein et al, 1994]. There are approximately 20-35 
potential N-glycosylation sites (PNGS) in gp120. Glycosylation plays a role in protein 
folding, immune evasion, and virion binding [Montefiori et al, 1988; Li et al, 2008]. 
Proper tertiary structure is also dependent on the formation of disulfide bridges. 
Generally, 18 Cys residues form 9 disulfide bridges. The V1 and V2 loops are separated 
by two disulfide bridges and contained within a larger loop formed by another disulfide 
bond. The V3 and V4 loops are also formed by disulfide bonds. Disruption of these 
bonds changes Env structure and may have effects on viral properties [Gao et al, 1996; 
Jobes et al, 2006]. 
gp41 
 As compared to gp120, gp41 is more conserved and arranged into three functional 
domains: the extracellular domain, the transmembrane domain (TMD), and the C-
terminal cytoplasmic tail (CT). The major function of the gp41 subunit is to mediate 
fusion and the major fusion determinants are contained within the extracellular domain 
[Bosch et al, 1989; Freed et al, 1990; Freed et al, 1992]. This domain has the N-terminus 
fusion peptide that is hydrophobic as well as two hydrophobic heptad repeat regions 
(HR1 and HR2) [Chan et al, 1997; Dubay et al, 1992; Lu et al, 1995; Tan et al, 1997; 
Weissenham et al, 1997], a polar region, and a membrane-proximal external region 
(MPER) [Munoz-Barroso et al, 1999; Salzwedel et al, 1999]. Fusion is primarily driven 
by interactions between the HR regions and exposure of the fusion peptide. Upon binding 
of CD4 and the coreceptor, a conformational change is induced that exposes the fusion 
peptide. The exposed peptide is able to penetrate the cellular membrane of target cells, 
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causing destabilization of the membrane and leading to the formation of the fusion pore 
[Brasseur et al, 1990]. Next a stable six-helix bundle is formed by the interaction of 3 
HR1 motifs and 3 HR2 motifs and brings the cellular and viral membranes together for 
fusion to occur. To form the six-helix bundle, the HR1 motifs form a core bundle and 
fold over a hydrophobic groove with the HR2 motifs [Chan et al, 1997; Weissenham et 
al, 1997]. HR1 and HR2 are both targets for antiretrovirals; peptides-derived from either 
heptad repeat are able to disrupt the formation of the six-helix bundle and prevent fusion 
[Furuta et al, 1998; Kilby et al, 1998; Wild et al, 1994]. 
 In addition to the fusion peptide, the MPER is also found within the extracellular 
domain and is involved in promoting fusion. It has been shown to be necessary for 
infectivity and fusogenicity, but the mechanism underlying the actions is unclear 
[Munoz-Barroso et al, 1999; Salzwedel et al, 1999].  It is known that this region is highly 
conserved and is a target of neutralizing antibodies [Cao et al, 1993; Zwick 2001]. 
 A second domain in gp41, the TMD, anchors Env in the lipid bilayer and consists 
of approximately 25 highly conserved amino acids. The TMD is necessary for Env 
function and mutations within this domain have been shown to interrupt fusion [Shang et 
al, 2008; Shang and Hunter, 2010; Kondo et al, 2010]. The traditional model for gp41 
topology suggests that the TMD forms an alpha helix that spans the membrane one time. 
With this scenario the entire CT would be contained within the virion. However, another 
model suggests gp41 spans the membrane three times exposing portions of the CT to the 
extracellular space [Kennedy et al, 1986; Steckbeck et al, 2010]. Current evidence favors 
the single pass model, but both models may exist [Hollier and Dimmock, 2005]. 
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 The third functional domain, the CT has multiple functions. Like other 
lentiviruses HIV-1, HIV-2, and SIV have a long CT when compared to other retroviruses 
[Rushlow et al, 1986; Rice et al, 1990]. The length of the CT contributes to its function as 
it has been shown that truncations in the CT of SIV suppress viral replication in rhesus 
macaques [Shacklett et al, 2000]. The HIV-1 CT has an impact on several properties of 
Env. Viral infectivity, Env incorporation into virions, gp120 shedding, Env cell-surface 
expression, gp120 and gp41 conformation, and fusion are all influenced by the CT. 
Evidence that the CT plays a role in modulating gp120 conformation is that mutations in 
the CT affect antibody recognition and neutralization, and truncations in the CT has been 
associated with CD4 independence [Edwards et al, 2001; Edwards et al, 2002; Kalia et al, 
2005]. 
 There is also evidence that potential interactions between gp120 and gp41 affect 
fusogenicity. Wang et. al. [2011] found that mutations that conferred resistance to a 
fusion inhibitor targeting HR1 clustered in both gp41 and gp120. Resistance was mapped 
primarily to the gp41 mutations, but the gp120 mutations were capable of enhancing 
fusion and this was related to the ability to utilize CD4 and CCR5. Another study found 
mutations in the gp41 ectodomain that produce an unstable gp120-gp41 complex 
correlate to a decrease in fusion function [Maerz et al, 2001]. Additionally, viruses that 
contain adaptive mutations in gp120 that allowed for usage of mutant forms of CCR5 
were capable of fusing at a quicker rate due to reduced constraints holding gp41 [Platt et 
al, 2007]. Given this evidence it is reasonable to suggest that differences in gp120 may 
play a role in Env-mediated fusion.  
Characteristics of HIV Env in perinatal transmission 
13 
 
 Several studies have highlighted the importance of Env in MTCT. The ability of 
variants to use CCR5 may play a role in transmission; newly transmitted viruses from a 
subtype C mother-infant-pair (MIP) MTCT cohort [Zhang et al, 2002] and a subtype A 
MIP cohort [Rainwater et al, 2007] were found to use CCR5 exclusively. Even minor 
variants with CCR5 phenotypes are selected for transmission in HIV-1 infected mothers 
during perinatal transmission and/or are amplified after transmission [Matala et al, 2001]. 
 Previous studies have demonstrated that, despite a complex viral population in the 
mother, only viruses of a restricted subset were typically transmitted to the infant [Ahmad 
et al, 1995; Contag et al, 1997; Lamers et al, 1993; Mulder-Kampinga et al, 1995; 
Samleerat et al, 2008; Scarlatti et al, 1993a; Scarlatti et al, 1993b; Scarlatti et al, 1993c; 
Verhofstede et al, 2003; Wolinsky et al, 1992; Zhang et al, 2002]. Controversy in the 
field of pediatric HIV-1 infection has involved whether selective transmission of a 
specific, homogeneous maternal viral population to the infant occurs in utero or 
intrapartum; studies have failed to pinpoint a specific timing for transmission [Contag et 
al, 1997; Mulder-Kampinga et al, 1995]. In some cases the transmitted strain was a minor 
variant of the maternal viral pool, and was due to selective pressures against V3 (Ahmad 
et al, 1995; Wolinsky et al, 1992).  Despite evidence of restrictive transmission as a 
characteristic of MTCT, several other groups have also reported a more random pattern 
of transmission, including of multiple and/or major maternal HIV-1 genotypes from 
mother to infant [Dickover et al, 2001; Lamers et al, 1994; Pasquier et al, 1998]. Mothers 
acutely infected with HIV-1 that underwent near simultaneous seroconversion with their 
infants transmitted a number of closely related viral variants [Hoffmann et al, 2008]. 
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Similarly, mothers with primary infection during pregnancy showed a random pattern of 
transmission [Ceballos et al, 2008]. 
 One source of selective pressure in perinatal transmission of HIV-1 is maternal 
antibodies, which could play a role in limiting transmission of neutralization sensitive 
variants. Studies have shown that nontransmitting mothers had more frequently 
detectable and/or higher levels of neutralizing antibody responses than transmitting 
mothers [Bongertz et al, 2002; Guevara et al, 2002; Lathey et al, 1999]. It has also been 
suggested that the virus variants more resistant to neutralization are preferentially 
transmitted perinatally [Scarlatti et al, 1993b]. A recent study found that variants from 
infants were more resistant to neutralization by maternal plasma than the overall maternal 
virus population [Rainwater et al, 2007; Wu et al, 2006]. Another study found that newly 
transmitted viruses from a cohort of subtype C MIP were more resistant to neutralization 
by paired maternal plasma than contemporaneous maternal plasma and more resistant to 
IgG b12, but were sensitive to pooled plasma [Zhang et al, 2010b]. In contrast, others 
have shown no notable differences between mother and infant viruses in sensitivity to 
heterologous plasma or the antibodies 2G12 and b12. A direct association between 
maternal antibodies against the V3 domain of the Env and a lower rate of transmission of 
HIV-1 has been suggested by some studies [Y Devash et al, 1990; Wu et al, 2006], but 
others have not found a correlation [Halsey et al, 1992; Parekh et al, 1991].  
 The number and location of PNGS may favor certain variants for transmission. 
Several studies have shown newly transmitted viruses have shorter variable loops and 
fewer PNGS [Russell et al, 2011; Wu et al, 2006; Zhang et al, 2010b); however, others do 
not observe this trend [Kishko et al, 2011; Samleerat et al, 2008; Thenin et al, 2009]. A 
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study of a cohort in Thailand examined the gp120 sequences from variants of CRF01_AE 
clade and found that the number of PNGS was not related to transmission. However, 
PNGS at positions N301 and N384 were conserved among all infant sequences and 
variable among mother sequences, suggesting a potential role in transmission [Samleerat 
et al, 2008]. Another study examined the V1-V5 and PNGS at N339 was found at a 
higher frequency in transmitting mothers than non-transmitting mothers. They also found 
that PNGS at N295 was in lower frequency in children than mothers [Baan et al, 2011]. 
The role of PNGS in MTCT is likely subtype specific. 
 Despite evidence that Env is playing a key role in MTCT, the functional role of 
Env in MTCT remains controversial. Neither Env processing nor incorporation into 
virions was found to predict transmission [Zhang et al, 2010b; Thenin et al, 2009]. Viral 
entry, which is dependent on Env, did not differ between mother and infant variants as 
measured by the response to entry inhibitors such as soluble CD4, PSC-Rantes, and 
TAK779 [Rainwater et al, 2007; Thenin et al, 2009]. However, replicative fitness 
mediated by V1-V5 was shown to be higher in infant viruses from chronically infected 
MIP [Kong et al, 2008]. The role of the biological functions of Env, such as binding and 
fusion, during MTCT still remains unclear and provides an avenue for further inquiry.  
Objective 
 Based on the previous data that demonstrated a role for V1-V5 in the higher 
replication fitness of transmitted viruses [Kong et al, 2008], our overall objective was to 
determine if this region had an effect on other biological properties of Env including 
fusion and binding. Our specific aims were: 
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1)  To determine if V1-V5 is capable of influencing fusion and if any differences 
that might exist correlate to replicative fitness and predict transmission. This was 
carried out by using a fluorescent resonance energy transfer (FRET) based virus-
to-cell fusion assay to measure the fusion efficiency in a transmitting MIP cohort 
from Zambia, and determined if any differences in fusion efficiency correlated to 
transmission. 
2) To determine if V1-V5 is capable of influencing CD4 binding and if any 
differences that might exist correlate to replicative fitness and predict 
transmission. This was carried out by a virus-to-cell binding assay to measure the 
binding efficiency of transmitting MIP from Zambia. We also correlated any 
differences to fusion and transmission. 
Our results demonstrated a positive correlation between fusion and infectivity, and there 
were variations between different clones in binding and fusion efficiencies. This variation 
suggests that differences in fusion and binding exist in a clone-to-clone manner, and are 
likely to be influenced by the V1-V5 region of Env. However, there was no correlation 
between binding and fusion activities of various Env clones and variations in fusion and 
binding among clones are not predictive of their ability to transmit from mother to infant.  
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Chapter 2: Virus to cell fusion of HIV-1 is influenced by envelope V1-




 Despite recent efforts and successes in reducing the incidence of perinatal 
transmission of HIV-1, MTCT still remains the dominant source of pediatric HIV-1 
infections and presents a serious concern in countries with the highest HIV prevalence. In 
these countries HIV-1 is the underlying cause of death in one-third of childhood 
mortalities for children under five years of age [Bennnett and Rogers, 1991; UNAIDS, 
2008]. In the absence of ART, perinatal transmission rates remain between 30-45%  in 
many developing countries [Bulterys et al, 1998; Lathey et al, 1999]. In sub-Saharan 
Africa, where HIV-1 infection is epidemic and access to ART is limited, perinatal 
transmission remains a major pediatric concern [Cooper et al, 2002]. Since prevention of 
MTCT remains a key goal in the global fight against HIV/AIDS, a better understanding 
of the possible mechanisms underlying MTCT, including functional properties of 
transmitted viruses, remains critical.  
 Many of the studies investigating transmitted viruses from mother-infant-pair 
(MIP) cohorts are contradictory. In general, restrictive transmission of a small viral 
subset appears to be a hallmark of MTCT in mothers chronically infected with HIV-1. In 
some cases where infection in the infant was established by a minor variant of the 
maternal viral pool; selection for the minor variant is attributable to pressures against V3  
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[Ahmad et al, 1995; Wolinsky et al, 1992]. Coreceptor usage, a function of V3, may play 
a role in transmission. In both a subtype C MIP cohort [Zhang et al, 2002] and a subtype 
A MIP cohort [Rainwater et al, 2007] newly transmitted viruses were found to use CCR5 
exclusively. Others have observed selection for minor variants with CCR5 phenotypes in 
HIV-1 infected mothers during perinatal transmission and/or amplification of CCR5 
using variants after transmission [Matala et al, 2001]. This data suggests a role for Env in 
determining perinatal transmission and that there is functional difference between the 
Env of transmitted and non-transmitted viruses. Neutralization sensitivity likely plays a 
role in transmission. Multiple studies have shown a relationship between low levels of 
neutralizing antibody response in mothers [Bongertz et al, 2002; Guevara et al, 2002; 
Lathey et al, 1999] and neutralization resistance [Scarlatti et al, 1993; Rainwater et al 
2007; Wu et al, 2006] and transmission. Some studies have proposed a direct association 
between maternal antibodies against the V3 domain of the Env and a lower rate of 
transmission of HIV-1 [Y Devash et al, 1990]. 
 The number and location of potential N-glycosylation sites (PNGS) in Env may 
also be a target of selection for certain variants during transmission. Newly transmitted 
viruses with shorter variable loops and fewer PNGS have been observed in many studies 
[Russell et al, 2011; Wu et al, 2006; Zhang et al, 2010]. PNGS at positions N301, N384 
[Samleerat et al, 2008] and N339 [Baan et al, 2011] are all associated with transmitted 
viruses. There also appears to be selection against PNGS at N295 [Baan et al, 2011].  
Sequential evidence suggests Env is playing a key role in MTCT; however, the 
functional role of Env in MTCT remains unknown. Neither Env processing nor 
incorporation into virions is predictive of transmission [Zhang et al, 2010; Thenin et al, 
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2009]. Env mediated-viral entry, measured by the response to entry inhibitors such as 
soluble CD4, PSC-Rantes, and TAK779, did not differ between transmitted and 
nontransmitted variants [Rainwater et al, 2007; Thenin et al, 2009]. However, our 
previous studies observed replicative fitness mediated by V1-V5 to be higher in infant 
viruses from chronically infected MIP [Kong et al, 2008]. Based on the data available we 
decided to further examine the functional role of Env during viral entry into target cells 
as a potential determinant of transmissibility. 
Entry of virus into target cells is determined mainly by Env function. Entry has 
two distinct stages, binding and fusion. While the fusion domain is found within gp41, 
fusion is subsequent to binding and may be influenced by both the structure and function 
of gp120. Thus, we hypothesized that gp120 may also be playing a role in influencing 
fusion, in addition to binding, which could contribute to the fitness advantage found in 
transmitted viruses.  
 
Materials and Methods 
 
Patient information 
 The subjects of this study were selected from a Zambian perinatal 
transmission cohort followed for HIV-1 infection. We chose five MIP (2669, 2617, 1084, 
1449, and 2873) for our current study. All the pairs chosen represented chronically 
infected mothers, mothers infected at delivery likely via sexual transmission, which 
transmitted to their infants. Venous blood was obtained from the mothers before delivery 
and HIV-1 serological status was determined by two rapid assays, Capillus (Cambridge 
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Biotech, Ireland) and Determine (Abbott laboratories), and confirmed by 
immunofluorescence assay. All mothers were HIV-1 positive at delivery and this was 
subsequently defined as baseline for mothers. 
Children from these MIPs represented both rapid (2669, 2617, 1449, 2873) and 
slow (1084) progressors as determined by clinical outcome and survival. Rapid 
progressors died within the first year of life due to HIV-related complications, while slow 
progressors were followed for more than four years and remained clinically 
asymptomatic. All children remained anti-retroviral naïve throughout the study. Venous 
blood was also obtained from the infants within 24 hours of birth and follow-up was 
maintained at 2, 4, and 6/8 months and at regular intervals through 48 months (for slow 
progressors). HIV-1 infection in the infants was detected by sequential viral isolation 
from the infants' peripheral blood mononuclear cells (PBMC), as previously described 
[Zhang et al, 2005] and by PCR of the HIV-1 provirus env gene from genomic DNA. 
HIV-1 isolation was unsuccessful from all samples and all infants were PCR negative at 
birth, suggesting either intrapartum or postpartum transmission. HIV-1 env sequences 
were amplified from infant PBMC at different postpartum time points. Due to the limited 
sample volume, viral isolation was prioritized over PCR when required (e.g., infant 1084, 
viral isolation was positive by 4 month and the first PCR was performed 6 month after 
birth) (Table 1). Mother samples were defined as baseline at the time of delivery. Infant 
samples were collected at the first postpartum, HIV-1 PCR positive time point.  
Viral Isolation 
A portion of the env gene from V1–V5 was amplified by PCR, cloned, and 
sequenced in order to characterize Env genetic diversification and evolution. Sequence 
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analysis from each MIP showed the mother and infant viruses were epidemiologically 
linked. All cases were subtype C based on Env, except for 1449 (subtype A/C 
recombinant). All viruses were also shown to be CCR5 tropic [Zhang et al, 2005]. 
Between four and six representative functional and fusion-positive Env clones from each 
MIP baseline were used for further analysis (Table 1). The V1-V5 fragments were 
ultimately cloned into a proviral expression vector, pNL4-3 A/S/AV, resulting in 
infectious molecular clone plasmids that express Env as a chimeric protein with the 
patient's Env V1-V5 region and HIV-1 strain NL4.3 (Fig.1) 
 
Cell cultures 
 293T and TZM-bl (NIH AIDS Research and Reference Reagent Program catalog 
no. 8129) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 
10% fetal bovine serum (FBS, Gibco) and 100ug/ml penicillin-streptomycin (Invitrogen). 
SupT1-CCR5 (from Dr. James Hoxie, Emory University) were maintained in RPMI with 
10% FBS, 100ug/ml penicillin-streptomycin, and 300ng/ml puromycin. All cells were 
grown at 37ºC with 5% CO2. 
 
Proviral expression constructs 
 The V1-V5 region of the env gene was amplified by nested PCR from uncultured 
patient PBMC using the Gentra Kit (Purgene), cloned into the pGEM-T Easy vector and 
sequenced as described [Zhang et al, 2006]. The Env V1-V5 region from selected clones 
was amplified from the pGEM-T Easy vector and subcloned into the pSP72 NLA/S/Av 
shuttle vector. The chimeric Env expression construct containing patient-derived Env V1-
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V5 region was generated by substituting the EcoRI-XhoI region of pSP72A/S/Av with 
the corresponding region of pSRH NL A/S/Av to screen for biological function as 
described [Zhang et al, 2010]. Functional envelope constructs were transferred into a 
proviral expression vector, pNL4-3 A/S/Av, by substituting EcoRI-XhoI region of pSRH 
NL A/S/Av with the corresponding region of pNL4-3 A/S/Av, resulting in infectious 
molecular clone plasmids with an NL4-3 backbone.  
 
Viral Production 
 Viruses bearing patient-derived Env V1-V5 and BlaM-Vpr were produced by 
calcium phosphate transfection of 293T cells. Approximately 2.0x10
6
 293T cells were 
transfected with 9ug of proviral construct, 3.0ug of pMM310 (BlaM-Vpr) (NIH AIDS 
Research and Reference Reagent Program catalog no. 11444), and 1.5ug of pAdVantage 
(from Dr. Gregory Melikyan, Emory University) in a 10cm dish. At minimum three 
dishes were used for each proviral construct. After 48 hours post-transfection, the 
infectious virus was harvested, centrifuged to clarify debris, and pooled. The viral stocks 
were concentrated by ultracentrifugation using the SW-41 Ti rotor (Beckman Coulter) or 
the SW 32 Ti rotor (Beckman Coulter) at 20,000rpm for 2 hours at 4ºC. The viral pellet 
was resuspended at a 30x-40x final concentration and stored at -80ºC. The amount of 
HIV-1 in the viral stocks was measured using the HIV-1 p24 ELISA kit (PerkinElmer 
Life Sciences, Inc.). Samples were diluted at 1:500,000 using DMEM culture media, 
mixed with the lysis buffer contained in the kit, added to the antibody-coated plates, and 
incubated at 4ºC overnight. All other steps were performed according the manufacturer 




Protein incorporation in virions 
 Western blot analysis was carried out to determine the incorporation of p24, 
gp120, and BlaM-vpr into virions. Viral stocks were normalized by p24 (as described 
above) and lysed for SDS-PAGE. Viral proteins were separated on a 4-20% agarose 
gradient gel, transferred to a nitrocellulose membrane and then analyzed by Western blot. 
A polyclonal goat anti-HIV-1 gp120 antibody (Thermo Scientific Pierce) was used to 
detect gp120, polyclonal rabbit anti- HIV-1 Vpr (1-46) antibody (NIH AIDS Research 
and Reference Reagent Program catalog no. 3951)  to detect vpr and BlaM-vpr, and 
polyclonal rabbit anti-HIV-1SF2 p24 antibody (NIH AIDS Research and Reference 
Reagent Program catalog no. 4250) to detect p24. Protein quantification was performed 
using the Odyssey Infrared Imager (Li-Cor). 
 
Fusion  
 Viruses containing the patient Env V1-V5 and BlaM-Vpr were used to measure 
virus-to-cell fusion in a fluorescent resonance energy transfer (FRET) based assay as 
previously described [Cavrois et al, 2002]. One day prior to infection SupT1-CCR5 cells 
were removed from puromycin selection. On the next day, 250,000 SupT1-CCR5 cells 
were transferred to each well of a 96-well V-bottom plate. Based on p24 ELISA data, 
50ng of p24 of each virus was added to the cells in a total volume of 100ul. Cells were 
incubated with virus for 2hrs at 37ºC with 5% CO2. After incubation the virus was 
removed from the cells and fusion was quantitated based on beta-lactamase activity using 
the GeneBLAzer in vivo Detection Kits (Invitrogen catalog no. 12578-134). A loading 
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solution containing a 1:4 ratio of CCF2-Am substrate, resuspended in DMSO (kit 
solution A), to Pluronic®-F127 surfactant in DMSO and acetic acid (kit solution B) in 
CO2-Independent media, was added to the cells and incubated for 1hr at room 
temperature in the dark. This solution was removed and the cells were washed with the 
CO2 -Independent media. A developing solution containing 2.5mM probenecid and 10% 
FBS in CO2 -Independent media was added to the infected cells, and then allowed to 
incubate overnight (16hrs) at room temperature in the dark. After overnight incubation 
the developing solution was removed from the cells, the cells were then washed, and 
fixed in 1.2% paraformaldehyde for flow cytometry analysis.  
 Upon virion fusion to the plasmid membrane, the BlaM-Vpr protein can be 
internalized into the cell. Cells with BlaM activity will demonstrate a shift in the CCF2-
AM FRET pattern from green to blue due to cleavage of CCF2-AM and are considered 
fusion positive. The change in emission patterns was observed by flow cytometry using a 
DxP 10 modified BDFacScan (Cytek Development Inc). CCF2-AM was excited at 
407nm. Green emission was detected with the 545/30 filter and blue emission was 




 Viral infectivity was measured by the tissue culture dose for 50% infectivity 
(TCID50) on TZM-bl cells. One day prior to infection, TZM-bl cells were plated at a 
density of 1.5 X10
4 
cells/100ul/well in a 96-well plate. Viral stocks were diluted 10-30-







) were made from this stock and transferred to the cells. Each virus dilution was done in 
quadruplicate. After 48 hours the virus was removed from the cells, the cells were then 
fixed and stained for beta-galactosidase activity. Viral titer was calculated as TCID50/ml 




V1-V5 of Env is capable of influencing fusion.  
 Chimeric viruses bearing patient-derived Env V1-V5 in a Subtype B, NL4.3 
backbone were used to assess the fusion capabilities of 5 MIPs. We used a FRET-based 
virus to cell fusion assay in order to quantify the percentage of cells that have undergone 
fusion. Infectious viruses were produced by a triple transfection of 293T cells with the 
proviral plasmid, the pMM310 (BlaM-Vpr) plasmid, and the pADVantage plasmid (used 
to boost translation). Virions produced by this method will incorporate the chimeric Env 
and package the BlaM-Vpr fusion protein.  
 We used the CCR5-tropic AYDA strain as a positive control for dye loading and 
BlaM activity. The AYDA V1-V5 was cloned into the NL4.3 backbone using the same 
strategy as the patient-derived Env variants. All fusion was plotted relative to AYDA as 
the reference clone. The AYDA clone consistently produced a strong positive signal with 
approximately 70% of the cells with a shift from green to blue fluorescence. In all MIPs 
tested clone-to-clone variation in fusion activities was observed (Fig. 2).  
 With MIPs 2617, 1449, 2873 fusion between patient-derived clones with target 
cells varied from 12.5-58.3%, 23.6-64.9%, and 27.9-48.7%, respectively. Relative fusion 
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activities of clones from MIP 2617 ranged from 43.7-104.8%, with clone M3 having the 
highest fusion and clone i3 the lowest (i indicates infant clones and M denotes mother 
clones in all designations). For MIP 1449 the mother clones had both the highest (M2) 
and lowest fusion (M3). Relative fusion activities of clones from MIP 1449 ranged from 
28.6-81.5%. For MIP 2873, relative fusion was between 39.4-68.9%. Once again with 
this pair the mother clones had both the highest (M1) and lowest fusion (M3), but fusion 
was very similar for all viral variants from this pair. For MIP 2669 and 1084, the 
differences in fusion were much more dramatic. Clone i1 from 2669 fused at least 2.5 
times greater than any other clone and 22 times greater than the weakest clone (mother 
M4). The M4 clone fused 4.3 times less than any other clone. Overall, fusion activities of 
clones from MIP 2669 varied from 59.4-95.5%. With MIP 1084 2 mother clones (M3 and 
M4) have high fusion activities, while all other clones have much weaker fusion activities 
compared to these clones and most of the other MIPs. The M3 and M4 fused 102.6% and 
115.6% relative to AYDA while all other clones fused less than 5%. Clone i3 fused less 
than 1%.  
 There was also wide clonal variation in fusion in viruses isolated from the same 
patient (Fig. 2). With 1084M fusion was 100 times greater with clones M3 and M4 
compared to M1. 1084i fusion varied by 8-fold amongst variants. In 2669M fusion varied 
over 9-fold between the lowest (M4) and highest (M2) clones. All other patients had a 2-
5-fold variation with clones from the same patient. 
 In order to rule out any differences in fusion caused by BlaM-Vpr incorporation 
into virions, western blots were performed on all viral preparations. The amount of 
BlaM-Vpr was measured using an antibody to vpr. We did not see a difference in BlaM-
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vpr incorporation between any of the MIP (data not shown). Any differences in fusion are 
thus attributable to Env. Since all clones also contained the same gp41 fusion domain 
from NL4.3, therefore the dramatic differences we see in fusion of these MIP are due to 
their differences in the V1-V5 region. 
 
Fusion activities cannot predict transmission.  
 Overall, there was no difference in fusion activities that can differentiate between 
the transmitted clones and non-transmitted viral clones. None of the MIP clones, 
individually or as a group, displayed a pattern in fusion capabilities that could predict 
whether they were derived from the mothers or from the infants (Fig 3). For MIP 2617 
and 1084, the mother viruses appeared to have a slight advantage in fusion over the infant 
viruses, but this was not significant. For MIP 2669, infant viruses have slightly higher 
fusion activities over mother viruses, but this is also non-significant. MIP 1449 showed 
similar fusion in both mother and infant viruses (Fig 3a). Overall, the mother viruses as a 
group had a slight advantage in fusion over infant viruses (Fig 3b). However, this 
advantage is not significant (p 0.097). In summary, wide clone-to-clone variation among 
clones from all patients, but there is no distinct pattern to fusion activities that are 
characteristic of the transmitted infant versus the non-transmitted maternal clones. 
 
Fusion correlates with infectivity.  
 We then tested the ability of the various maternal and infant viral clones to infect 
target cells. Viral infectivity was measured by titration on TZM-bl cells. Infectivity was 
found not to be predictive of transmission. Infectivity of the viral clones from mother and 
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infant pairs varied within a transmission pair, and among all the clones obtained from the 
cohort (Fig. 4). In general, clones within a pair varied up to 15 times in terms of 
infectivity. For example, for MIP 2669 clone i1 has much higher infectivity than the other 
clones, with infectivity 40 times greater than that of the least infectious clone. MIP 1084 
demonstrated a more variable pattern of infectivity. Once again, infectivity of 1084 viral 
clones M3 and M4 were much higher than the other clones. When excluding these two 
viral clones, other 1084 isolates were more similar to each other (varied by less than 10 
times) and were similar to other viral clones obtained from other MIPs. Overall, fusion 
activity correlates to infectivity (Table 2). For pairs 2669, 1084, and 2873 fusion 
correlated strongly with infectivity as measured by viral titer, with R
2
 values of 0.899, 
0.992, and 0.885, respectively. MIP 1449 showed a slightly lower correlation with an R
2
 
of 0.764. MIP 2617 was the only pair that did not show a strong correlation between 
infectivity and fusion (R
2
 0.204). This pair demonstrated much less variation in fusion 
than other pairs, but still displayed variation in infectivity that was similar to other MIPs. 
 
Incorporation of Env into virions does not determine fusogenicity.  
 In order to determine whether fusogenicity and infectivity of the various viral 
clones were affected by the amount of Env gp120 incorporated into the virion, we 
determined and compared the gp120 incorporation into each viral clone by western blot. 
Equal amounts of virus was lysed and loaded onto a gradient gel based on viral titer 
determined by p24 ELISA. Both p24 and gp120 were detected. Env incorporation was 
based on the amount of Env detected after normalizing to the amount of input viruses 
based on the p24 signal (Fig 5). Env incorporation did not significantly differ between the 
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mother and infant viral clones from the MIPs except 2873. Although infant viruses from 
MIP 2669 appear to have a higher Env incorporation, this trend was not significant (t-test, 
p 0.113). For MIP 2873 the mother viruses incorporated slightly more Env than infant 
viruses (t-test, p 0.025). For MIP 1084 clone M4 also incorporated more Env than the 
other clones. However, there is no correlation between fusion activities and the amount of 
Env incorporated by different viral clones (Table 3). Only clones from MIP 1084 showed 
some correlation between fusion and Env incorporation (R 0.826, R
2
 0.682). For MIP 
1084 clones M3 and M4 showed a dramatic increase in fusion compared to the other 
clones. There was correlation observed between incorporation and fusion for these two 
clones, the higher levels of Env incorporation may have resulted in their higher fusion 
activities. Whereas for the variants from 1084 that have similar fusion activities there 
appeared to be a slight inverse relationship between fusion and incorporation (R -0.807), 
but this correlation is not very strong (R
2
 0.651). This is likely due to clone i3 which had 
very low fusion despite incorporating a relatively high amount of Env, suggesting there 
may be some qualitative difference among different Env in their ability to mediate fusion 




 Our previous study showed that V1-V5 of env is capable of influencing 
replicative fitness of viral variants from MIP and the fitness is predictive of transmission 
[Kong et al, 2008]. However, envelope mediated fusion fails to explain a higher 
replicative fitness in infant viruses and does not predict transmission. Previously, we had 
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also observed that Env synthesis and processing, viral infectivity, replication kinetics, and 
Env incorporation into virions failed to predict transmission [Zhang et al, 2010]. The 
fusion results agree with the other functional data that suggests Env functions measured 
do not predict transmission and viral replicative fitness. It is likely that at least some of 
the discordance between replicative fitness and the other functional properties of Env that 
have been measured from clones from these MIP can be attributed to differences in viral 
preparations. The fitness assay represents a more heterogeneous viral population because 
the virus used was prepared by allowing for a recombination of the env as a PCR product 
and an env deficient backbone. The other properties were all measured with full-length 
proviral clones and represent a homogeneous viral population. The fitness assay also used 
a long incubation time that measured multiple rounds of replication that likely included 
recombination events between the mother and infant clones.  Of the biological properties 
of Env that were measured in this study, only infectivity measures multiple rounds of 
replication. However, the incubation time for fitness is over twice as long as infectivity. It 
is likely that the very early infection events measured in the current study are different 
from later events and explains, at least in part, why fitness and fusion data do not 
correlate. 
 This study demonstrated a correlation between the fusion activities and 
infectivities of the viral clones that was expected. Fusion is a key part of the entry process 
and initiates infection. We would expect that viral variants with higher fusion activities 
are more capable of entering target cells and this is reflected in infectivity measured in 
the first few rounds of replication. We did not see a correlation between fusion activities 
of viral clones and the amount of Env incorporated into virions of the clones. The lack of 
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a correlation between these two Env properties of the viral clones suggests that there are 
some qualitative differences in Env from these clones.   
This study does show that V1-V5 of env is capable of influencing fusion, even 
though all variants contained the same fusion domain (gp41). This is possibly due to the 
stability of the gp120-gp41 complex. Recent studies have shown potential interactions 
between gp120 and gp41 affect fusogenicity. Mutations in the gp41 ectodomain that 
produce an unstable gp120-gp41 complex correlate to a decrease in fusion function 
[Maerz et al, 2001]. This study also suggests that there are some biological differences 
found in the Env variants isolated within a patient. Within a patient (2669M) high and 
low fusing clones vary by seven times and this is not due to the amount of Env 
incorporated into the virions. Thus, fusion in general is not simply determined by the 
amount of Env expressed on the virion. However, there are exceptions. For example, for 
variants 1084 M3 and 1084 M4 the levels of Env incorporation are contributing to the 
dramatically higher fusion and even for these clones Env incorporation alone cannot 
account for the differences in fusion. It is possible that primary sequence differences 
between different env clones may influence their fusion activities. However, upon 
preliminary analysis there does not appear to be any common mutations, insertions, or 
deletions that are characteristics of the Env with either high or low fusion activities. It is 
likely that the Env conformation may play an important role in influencing fusion. Post-
secondary modifications, such as glycosylation, that effect protein folding and stability 
are potential determinants of fusogenicity. Additionally, viruses that contain adaptive 
mutations in gp120 that allowed for usage of mutant forms of CCR5 were capable of 
rapid fusion kinetics due to a reduced constraint on gp41 in mediating fusion [Platt et al, 
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2007]. Finally mutations that accumulated in gp120 in response to fusion inhibitors were 
capable of enhancing fusion and this was related to the ability of these mutations to 
utilize both CD4 and CCR5 [Wang et al, 2011]. Env stability and CD4/CCR5 utilization 
should be further characterized in our clones to better understand the fusion properties 
and whether higher fusion activities correlate to their ability to use other coreceptors in 
addition to CCR5. 
In summary, our data suggests that the gp120-gp41 interaction is important in 
determining the functional properties of Env including fusion, but fusion is not predictive 
of perinatal transmission. However, it is likely that the Env structure and its stability may 





Ahmad, N., B. M. Baroudy, R. C. Baker, and C. Chappey. 1995. Genetic analysis of 
human immunodeficiency virus type 1 envelope V3 region isolates from mothers and 
infants after perinatal transmission. J. Virol. 69:1001-12. 
 
Baan, E., A. de Ronde, S. Lutchers, J. Vyankandondera, J. M. Lange, G. Pollakis, 
and W. A. Paxton. 2011. HIV type 1 mother-to-child transmission facilitated by 
distinctive glycosylation sites in the gp120 envelope glycoprotein. AIDS Res. Hum. 
Retroviruses. Epub ahead of print. 
 
Bennett, J. V., and M. F. Rogers. 1991. Child survival and perinatal infections with 
human immunodeficiency virus. Am. J. Dis. Child. 145:1242-7. 
 
Bongertz, V., C. I. Costa, V. G. Veloso, B. Grinsztejn, E. C. Filho, G. Calvet, and J. 
H. Pilotto. 2002. Neutralization titres and vertical HIV-1 transmission. Scand. J. 
Immunol. 56:642-4. 
 





Cavrois, M., C. de Noronha, and W. C. Greene. 2002. A sensitive and specific 
enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. 
Biotechnol. 20:1151-1154. 
Cooper, E. R., M. Charurat, L. Mofenson, I. C. Hanson, J. Pitt, C. Diaz, K. Hayani, 
E. Handelsman, V. Smeriglio, R. Hoff, and W. Blattner. 2002. Combination 
antiretroviral strategies for the treatment of pregnant HIV-1-infected women and 
prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29:484-94. 
 
Coutsoudis, A., F. Dabis, W. Fawzi, P. Gaillard, G. Haverkamp, D. R. Harris, J. B. 
Jackson, V. Leroy, N. Meda, P. Msellati, M. L. Newell, R. Nsuati, J. S. Read, and S. 
Wiktor. 2004. Late postnatal transmission of HIV-1 in breast-fed children: an individual 
patient data meta-analysis. J. Infect. Dis. 189:2154-66. 
 
Guevara, H., J. Casseb, L. S. Zijenah, M. Mbizvo, L. F. Oceguera, 3rd, C. V. 
Hanson, D. A. Katzenstein, and R. M. Hendry. 2002. Maternal HIV-1 antibody and 
vertical transmission in subtype C virus infection. J. Acquir. Immune Defic. Syndr. 
29:435-40. 
 
Kong, X., J. T. West, H. Zhang, D. M. Shea, T. J. M’soka, and C. Wood. 2008. The 
HIV-1 envelope confers higher replicative fitness to perinatally transmitted viruses. J. 
Virol. 82: 11609-11618. 
 
Lathey, J. L., J. Tsou, K. Brinker, K. Hsia, W. A. Meyer, 3rd, and S. A. Spector. 
1999. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 
(HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J. 
Infect. Dis. 180:344-50. 
 
Maerz, A. L., H. E. Drummer, K. A. Wilson, and P. Poumbourios. 2001. Functional 
analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency 
virus type 1 gp41 reveals a critical role in gp120-gp41 association. J. Virol. 75:6635-44. 
 
Matala, E., T. Hahn, V. R. Yedavalli, and N. Ahmad. 2001. Biological 
characterization of HIV type 1 envelope V3 regions from mothers and infants associated 
with perinatal transmission. AIDS Res. Hum. Retroviruses 17:1725-35. 
 
Platt, E. J., J. P. Dumin, U. Shinde, and D. Kabat. 2007. An allosteric rheostat in HIV-
1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes 
diverse entry limitations. J. Mol. Biol. 374:64-79. 
 
Rainwater, S. M., X. Wu, R. Nduati, R. Nedellec, D. Mosier, G. John-Stewart, D. 
Mbori-Ngacha, and J Overbaugh. 2007. Cloning and characterization of functional 





Russell E. S. , J. J. Kwiek, J. Keys, K. Barton, V. Mwapasa, D. C. Montefiori, S. R. 
Meshnick, and R. Swanstrom.  2011. The Genetic Bottleneck in Vertical Transmission 
of Subtype C HIV-1 Is Not Driven by Selection of Especially Neutralization-Resistant 
Virus from the Maternal Viral Population. J. of Virol. 85:8253–8262. 
 
Samleerat T., M. Braibant, G. Jourdain, A. Moreau, N. Ngo-Giang-Huong, P. 
Leechanachai, J. Hemvuttiphan,T. Hinjiranandana, T. Changchit, B. Warachit, V. 
Suraseranivong, M. Lallemant and F. Barin. 2008. Characteristics of HIV type 1 
(HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 
subtype CRF01_AE. J. Infect. Dis. 198:868–876. 
 
Scarlatti, G., J. Albert, P. Rossi, V. Hodara, P. Biraghi, L. Muggiasca, and E. M. 
Fenyo. 1993. Mother-to-child transmission of human immunodeficiency virus type 1: 
correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168:207-
10. 
 
Thenin, S., T. Samleerat, G. Jourdain, N. Ngo-Giang-Huong, A. Moreau, P. 
Leechanachai, M. Lallemand, F. Barin, and M. Braibant. 
 
2009. Maternal neutralizing 
antibodies against a CRF01_AE primary isolate are associated with a low rate of 
intrapartum HIV-1 transmission in Thailand. Retrovirology 6(Suppl 1):P5. 
 
UNAIDS. 2008. 2008 Report on the global AIDS epidemic. Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 2008. Retrieved from http://www.unaids.org/ 
en/dataanalysis/epidemiology/2008reportontheglobalaidsepidemic/ July 2008. 
 
Wang, W., C. J. De Feo, M. Zhuang, R. Vassell, and C. D. Weiss. 2011. Selection 
with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 
identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors 
corresponding to the first and second heptad repeats (HR1 and HR2) of gp41. J. Virol. 
85:12929-38. 
 
Wolinsky, S. M., C. M. Wike, B. T. Korber, C. Hutto, W. P. Parks, L. L. 
Rosenblum, K. J. Kunstman, M. R. Furtado, and J. L. Munoz. 1992. Selective 
transmission of human immunodeficiency virus type-1 variants from mothers to infants. 
Science 255:1134-7. 
 
Wu, X., A. B. Parast, B. A. Richardson, R. Nduati, G. John-Stewart, D. Mbori-
Ngacha, S. M. Rainwater, and J. Overbaugh. 2006. Neutralization escape variants of 
human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 
80:835-44. 
 
Y Devash, T. A. C., D G Wood, K J Reagan, and A. Rubinstein. 1990 May. Vertical 
transmission of human immunodeficiency virus is correlated with the absence of high-
48 
 
affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc. 
Natl. Acad. Sci. U.S.A. 87(9): :3445–3449. 
 
Zhang, H., G. Orti, Q. Du, J. He, C. Kankasa, G. Bhat, and C. Wood. 2002. 
Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C 
mother-to-child transmission. AIDS Res. Hum. Retroviruses 18:1415-23. 
 
Zhang, H., F. Hoffmann, J. He, C. Kankasa, R. Ruprecht, J. T. West, G. Orti, and 
C. Wood. 2005. Evolution of a subtype C HIV-1 Env in a slowly progressing Zambian 
infant. Retrovirology 2:67. 
 
Zhang, H., F. Hoffmann, J. He, X. He, C. Kankasa, J. T. West, C. D. Mitchell, R. M. 
Ruprecht, G. Orti, and C. Wood. 2006. Characterization of HIV-1 subtype C envelope 
glycoproteins from perinatally infected children with different courses of disease. 
Retrovirology 3:73. 
 
Zhang, H., M. Rola, J. T. West, D. C. Tully, P. Kubis, J. He, C. Kankasa, and C. 
Wood. 2010. Functional properties of the HIV-1 subtype C envelope glycoprotein 




Figure Legend  
 
Fig. 1. Organization of proviral plasmids. The V1-V5 region from each viral isolate of 
the MIPs was cloned into a NL4-3 backbone to produce an infectious molecular clone 
plasmid. Env is expressed as a chimeric protein. 
Fig. 2. Relative fusion. Fusion was examined using a FRET-based assay. Virions are 
produced by transfection in 293T cells and incorporate the chimeric Env protein with V1-
V5 from the patients and package a BlaM-Vpr fusion protein. Infections are done in 
SupT1-CCR5 cells and then cells are loaded with CCF2-AM and express a green 
fluorescence. Upon fusion, the BlaM-Vpr protein enters the cell and cleaves CCF2-AM 
producing a blue fluorescence. Fusion is quantified as the total percentage of blue cells. 
For each pair AYDA is used as a positive control and relative fusion is calculated as a 
percentage of the AYDA signal. Each graph represents at least four experiments, except 
2873 which only represents two  
Fig 3. Fusion of infant versus mother viruses. A. Comparison of infant (◊) and mother 
(o) variants with patient-derived V1-V5 for each transmission pair.  B. Comparison of all 
infant (◊) and mother (o) variants. The p value was calculated using a two-tailed Student 
paired t-test and is shown. 
Fig. 4. Infectivity of MIP-derived viruses. Viral stocks were titrated on TZM-bl cells 
and infectivity was measured as the TCID50/ml. Four fold serial dilutions were made 
from viral stocks and transferred to the cells. After 48 hours the virus is removed and 
cells are fixed and stained for beta-galactosidase activity. The TCID50/ml was measured 
using the Reed-Muench method. 
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Fig. 5. Env incorporation into virions. Western blot analysis was done to determine the 
incorporation of gp120 into virions. Viral stocks were normalized by p24. Viral proteins 
were separated on a 4-20% agarose gradient gel, transferred to a nitrocellulose membrane 
and analyzed by Western blot. A polyclonal goat anti-HIV-1 gp120 antibody (Thermo 
Scientific Pierce) was used to detect gp120 and polyclonal rabbit anti-HIV-1SF2 p24 
antibody (NIH AIDS Research and Reference Reagent Program catalog no. 4250) to 
detect p24. Protein quantification was performed using the Odyssey Infrared Imager (Li-
Cor). Env incorporation into virions was calculated as the gp120/p24 ratio; the NL4-3 













2669 Infant 2 mo. 3 CCR5 Rapid Bronchitis
Mother Delivery 3 CCR5 
2617 Infant 2 mo. 3 CCR5 Rapid Pyrexia
Mother Delivery 3 CCR5
1084 Infant 6 mo. 3 CCR5 Slow Survived
Mother Delivery 3 CCR5
1449 Infant 2 mo. 2 CCR5 Rapid Pneumonia
Mother Delivery 2 CCR5
2873 Infant 2 mo. 3 CCR5 Rapid Tuberculosis
Mother Delivery 3 CCR5
Table 1. Summary of mother and infant transmission pairs.







































































































































































































































































Table 2. Correlation between infectivity and 
fusion. 
0.885 0.941 2873 
0.764 0.874 1449 
0.992 0.996 1084 
0.204 0.452 2617 
0.899 0.948 2669 



































































































Table 3. Correlation between Env incorporation and 
fusion. 
 
0.335 0.578 2873 
0.344 0.587 1449 
1 1 *M3, M4 
0.651 -0.807 *i1, i2, i3, M1 
0.682 0.826 1084 
0.184 0.429 2617 
0.164 0.404 2669 
R2 R value MIP 
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Chapter 3: Virus to cell binding of HIV-1 is influenced by envelope V1-





Viral entry into target cells is a multi-step process that is initiated by the binding 
of virions to the viral receptor, CD4. Upon CD4 engagement, a conformational change is 
induced in Env that exposes the V3 loop and the coreceptor binding site. Engagement of 
the coreceptor, CCR5 or CXCR4, another conformational change occurs that exposes the 
fusion domain. Fusion then occurs subsequent to binding. Both binding and fusion are the 
primary functions of Env. 
The major role of gp120 is in binding the virion to the target cell. There are 
multiple CD4 binding sites within gp120 that are brought into the proper conformation by 
the gp120 tertiary structure to allow for CD4 binding [Lasky et al, 1987; Kowalski et al, 
1987; Olshevsky et al, 1987]. The coreceptor, both CCR5 and CXCR4, binding site is 
located in the V3 loop, but other domains within the V1-V5 region can also be involved 
to strengthen or weaken binding [Cann et al, 1992; Chesebro et al, 1991; Hwang et al, 
1991; O'Brien et al, 1990; Shioda et al, 1991]. Coreceptor usage is determined by the 
gp120 sequence; specific mutations within V3 facilitate the switch from CCR5 (R5) to 
CXCR4 (X4) usage [Fouchier et al, 1992; Pollakis et al, 2004]. V3 also plays a role in 
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membrane fusion [Freed et al, 1991] and contains epitopes for neutralizing antibodies 
[Goudsmit et al, 1988; Palker et al, 1988; Rusche et al, 1988].  
As the main function of gp120 of env is viral binding, we sought to compare the 
binding efficiencies of the V1-V5 region of the gp120derived from viruses isolated from 
subtype C infected mother-infant-pairs (MIP) and determine whether their binding 
abilities can predict transmitted viruses during perinatal transmission, and if it is 
contributing to higher replicative fitness in infant viruses from our cohort. We also sought 
to examine the relationship between binding and fusion as we examined fusion using the 
FRET-based assay (previously described) in parallel with binding. 
We examined binding in three of the MIPs (2669, 2617, and 1084) described 
previously. All these pairs represent chronically infected mothers with their infants 
classified as rapid (2617, 2669) versus slow (1084) progressors. It is also important to 
note that all the viral variants examined for binding use CCR5 for entry. We sought to 
examine binding using the EGFP/DsRed2 expressing viruses that were used for the 
growth competition assay [Kong et al, 2008]. We also used viruses without any marker to 
examine binding. In addition, we decided to examine fusion and binding in parallel and 
used the SupT1-CCR5 cell line and the BlaM-Vpr containing viruses.  
 
 






 The three mother infant pairs (2617, 2669, 1084) in this study have been 
described previously [Zhang et al, 2006]. All mothers were HIV-1 positive at delivery, 
asymptomatic, and not undergoing ART. The infants were all breast-fed and drug naïve 
as well. Mother samples were defined as baseline at the time of delivery. Infant samples 
were collected at the first postpartum, HIV-1 PCR positive time point.  
 
Cell cultures 
 293T and TZM-bl (NIH AIDS Research and Reference Reagent Program catalog 
no. 8129) cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 
10% fetal bovine serum (FBS, Gibco) and 100ug/ml penicillin-streptomycin (Invitrogen). 
SupT1-CCR5 (from Dr. James Hoxie, Emory University) were maintained in RPMI with 
10% FBS, 100ug/ml penicillin-streptomycin (pen/strep), and 300ng/ml puromycin. U87 
(NIH AIDS Research and Reference Reagent Program catalog no. 2188) cells were 
maintained in DMEM with 10% FBS and 100ug/ml pen/strep. U87.CD4.CCR5 cells 
(from Dr. Lee Ratner, Washington University) were maintained in DMEM with 10% 
FBS, 4mM Glutamine, 1mM Sodium Pyruvate, 200 µg/ml G418, and 1 µg/ml 
Puromycin. All cells were grown at 37ºC with 5% CO2. 
 
Proviral expression constructs 
 The V1-V5 region of env gene was amplified by nested PCR from uncultured 
patient PBMC using the Gentra Kit (Purgene), cloned into the pGEM-T Easy vector and 
sequenced as described [Zhang et al, 2006]. Generation of infectious molecular clone 
plasmids with MIP-derived Env V1-V5 and an NL4-3 backbone was described 
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previously. The chimeric env region was also substituted into the 4-3 EGFP/DsRed2 
using EcoRI and BamHI, resulting in molecular clone plasmids that express either EGFP 
or DsRed2.  
 
Viral Production 
 Viruses bearing patient-derived Env V1-V5 and BlaM-Vpr were produced as 
described previously. (NIH Awith or without EGFP/DsRed2 were produced by 
transfection of 293T cells using the FuGENE 6 (Roche). 1.5x10
5
 293T cells were 
transfected with 1.5ug of proviral DNA and 5ul of FuGENE in 1 well of a 6-well plate. 
The total volume in each well was 2ml and multiple wells were combined for each virus. 
Viral stocks were filtered through 0.45um filters and stored at -80ºC. All viral stocks 
were measured using a HIV-1 p24 ELISA kit (PerkinElmer Life Sciences, Inc.). Samples 
were diluted 1:500,000 using DMEM culture media, mixed with the lysis buffer 
contained in the kit, added to the antibody-coated plates, and placed at 4ºC overnight. All 
other steps were performed according the manufacturer protocol.  
 
Virus-to-cell Binding 
 Binding of viruses containing the patient Env V1-V5 with or without 
EGFP/DsRed2 was done in U87-derived cells. One day prior to the assay U87 and 
U87.CD4.CCR5 cells were plated at 4x10
5
/well in 1 well of a 6-well plate. The next day 
40ng of p24 of each virus was added to the cells and incubated for 1hr at 4ºC. Cells were 
vigorously washed with PBS. A lysis buffer containing 0.5% NP40 was added to the 
plates and cells were collected in Eppendorf tubes. Cultures were lysed at 4ºC for 1hr 
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with constant agitation. Lysates were clarified by centrifuging at 10,000xg for 10min and 
assayed for bound p24 by p24 ELISA as described above. Relative binding is determined 
using the U87 cell line to measure background signal (non-specific binding) and 
expressed as a fold increase over this level.   
 Binding of viruses containing the patient Env V1-V5 and BlaM-Vpr was carried 
out with SupT1-CCR5 cells. One day prior to infection SupT1-CCR5 cells were removed 
from puromycin selection. On the next day, 250,000 SupT1-CCR5 cells were transferred 
to each well of a 96-well V-bottom plate. Based on p24 ELISA data, 50ng of p24 of each 
virus was added to the cells in a total volume of 100ul of CO2-independent media. Cells 
were incubated with virus for 2hrs at 4⁰ C. After 2hrs cells were washed with PBS to 
remove unbound virus. Cells were lysed in a solution containing 0.5% Triton X-100 for 1 
hr at 4⁰ C. Lysates were clarified by centrifugation at 10,000xg for 10min. Bound p24 in 
the lysate was measured by p24 ELISA as described above. Percent binding was 
calculated as the bound p24/input p24x100. 
 
Virus-to-cell Fusion  
 Viruses containing the patient Env V1-V5 and BlaM-Vpr were used to measure 
virus-to-cell fusion in a fluorescent resonance energy transfer (FRET) based assay as 
previously described [Cavrois et al, 2002]. Virus-to-cell fusion was performed as 








Env V1-V5 influences viral binding in adherent cells 
 Initially, we sought to determine virus-to-cell binding in adherent cell lines using 
the U87 and U87.CD4.CCR5 cell lines. To determine binding we incubated U87 and 
U87.CD4.CCR5 cells with viral preps at 4ºC to prevent fusion. Next we attempted to 
wash away any unbound virus, collected and lysed the cells, and assayed bound p24 
using an ELISA. The U87 cell line was used to determine the background signal of the 
assay (a combination of unbound virus and non-specific binding). Relative binding was 
then measured as fold-increase over the background. First, we tested binding using MIP 
1084 and viruses with either an EGFP (infants) or DsRed2 (mothers) fluorescent tag. We 
saw a small clone-to-clone variation in viral isolates from MIP 1084 (Figure 1a). Clones 
i3, M2, and M3 all showed similar levels of relative binding at 1.92, 1.98, and 1.72, 
respectively. Clone i1 showed a slightly elevated binding at 2.60. However, when we 
attempted to test relative binding in non-tagged virus this pattern did not remain 
consistent. A representative experiment is shown in Figure 2a. All clones in this 
experiment had similar levels of binding, ranging from 1.42-2.29. In contrast to the 
previous experiment, clone i1 showed a lower binding (1.76) than other infant clones, but 
it was still higher than the mother clones (M1 1.44, M3 1.42).  
 
Binding does not predict transmission in adherent cells. 
 Overall, the relative binding is not predictive of transmission. When using the 
non-tagged viral preparations; we observed a trend towards higher binding in the infants 
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(p=0.056, Fig. 2b). However, we did not observe the same trend using the fluorescently-
tagged viral stock (p=0.303, Fig. 1b). Ultimately we were unable to resolve these 
discrepancies. While there might be a trend towards higher binding in infant viruses; the 
role of binding as an indicator of transmission remains unclear. 
 
Env V1-V5 influences viral binding in suspension cells 
 Next, we observed fusion in suspension cells. We used the same SupT1-CCR5 
that we had previously used to determine fusion. As we assayed for both fusion and 
binding concurrently in this set of experiments, we used the viral stocks with the BlaM 
marker. To determine binding we incubated SupT1-CCR5 cells with viral preps at 4ºC, 
washed away any unbound virus, lysed the cells, and assayed bound p24 using an ELISA. 
In this assay binding is measured as the percentage of bound virus and calculated as 
bound virus/input virus x 100. We tested three MIPs (2669, 2617, 1084). Overall, we saw 
very little binding in this assay (Fig. 3a-c). The highest percent binding observed was 
3.34% (2669 M4). A majority of the clones bound less than 1% of the initial virus 
available. In the case of 1084, less than 0.1% of viruses were capable of binding. In the 
case of MIPs 2669 and 2617, differences in binding between clones could be quite 
significant. For 2669, binding varied up to 10-fold between the highest (M2 3.33%, M4 
3.34%) and lowest (i3 0.30%) clones. In 2617 binding varied over 30-fold between M5 
(2.50%) and i1 (0.075%). MIP 1084 showed much less variation in binding among the 
clones, varying less than 2% between all clones.  
 
Binding does not correlate with fusion and does not predict transmission 
66 
 
 We examined binding and fusion concurrently in the SupT1-CCR5 cells. Unlike 
with the binding assay, cells were incubated with virus at 37ºC to allow binding to 
progress through fusion and entry to be completed. Fusion was assayed as described 
above. We see a difference in fusion among viral variants from each MIP (Fig. 3d-f). 
However, this difference in fusion does not correlate to the differences in binding (Table 
1). In fact, both MIP 2617 and 1084 showed an inverse relationship. This relationship is 
not significant as the correlation was extremely weak at R= -0.192 and R= -0.027 for 
MIP 2617 and 1084 respectively. MIP 2669 showed a positive and stronger correlation at 
R= 0.424, but again this is not significant.  
 Neither binding nor fusion were capable of predicting transmission in any of the 
MIPs we assayed (Fig. 4). Despite dramatic differences among clones in binding and 
fusion, there was no pattern between mother and infant clones that could distinguish them 
from each other (Fig. 4a). MIP 2669 was the closest to approaching a significant trend 
(p=0.192), with mother clones having a higher average binding. For 2669, mother clones 
averaged 2.366% binding and infants averaged 0.535% binding. However, variation in 
binding was high among the mother clones with M3 binding similar levels to the infant 
clones and preventing a clear trend for transmission from emerging. MIP 2617 had a 
similar trend as 2669, where mother clones had a higher average binding (0.928%) than 
infants (0.175%). This trend was also not significant (p=0.417). The difference in binding 
between mothers and infants can be attributed to one clone (M4) that bound much more 
than any other clone. MIP 1084 had similar levels of binding among all clones and the 







 Our previous studies showed that V1-V5 of env is capable of influencing 
replicative fitness of viral variants from MIP and the fitness is predictive of transmission 
[Kong et al, 2008]; however, Env synthesis and processing, viral infectivity, replication 
kinetics, and Env incorporation into virions failed to predict transmission [Zhang et al, 
2010]. We have also shown that Env fusion does not predict transmission. In this study 
we have also shown that viral binding does not predict transmission and cannot account 
for the differences that were observed in replicative fitness. As with fusion we can 
hypothesize we failed to find a correlation between binding and replicative due in part to 
measuring a single round versus multiple rounds of infection.  
 In all cell types and with all viral preparations we observed variation in binding 
abilities from the clones derived from the MIPs. However, we did not see a correlation 
between binding activities and fusion activities in any of the clones derived from the 
MIP. It is possible that a correlation does not exist, because bound virus is inactivated 
due to non-productive endocytosis, endocytosis that does not lead to fusion [Miyauchi et 
al, 2009]. Our binding assay may be measuring virus that is bound to CD4, but is 
incapable of binding to CCR5 and thus will not complete fusion. Another study found 
that monoclonal antibody (MAb) inhibition of HIV-1 entry and fusion did not correlate 
with inhibition of binding of a gp120-sCD4 complex to CCR5 positive cells [Olson et al, 
1999]. It has been hypothesized that entry has three distinct stages, receptor binding, 
coreceptor binding, and fusion. There may be common factors that are capable of 
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influencing all three stages, but it is possible that these stages are semi-independent of 
each other.  
 There was a major limitation in our study due to the methodology. There was a 
high level of variation between experiments and within experiments; producing a large 
standard deviation that remained above the mock infection, but close to these levels. The 
major drawback of this methodology appears to be an inability to distinguish a true 
positive signal from background. This problem could be due to an over representation of 
background (unbound virus that is not washed away), an under representation of bound 
virus (cells or virus that is washed away), or a combination of both. These factors could 
also account for differences we see between the different viral preparations. We would 
expect the same trends to be seen in the EGFP/DsRed2 viruses, the BlaM viruses, and the 
viruses without any markers. However, we do not see a repeatable trend. There is a slight 
possibility that the addition of the marker to the proviral clones affects the other 
biological properties of the viruses and is producing the differences that are observed 
between the different viral preparations. For example, we do see a lower viral titer of 
viruses containing the BlaM-Vpr fusion protein compared to viruses produced from 
proviral constructs without a marker. Another method must be applied to measure viral 
binding to confirm our results and draw conclusions about the role viral binding plays 
during transmission.   
 In summary, our data suggests that the Env V1-V5 region derived from subtype C 
transmitting MIP is capable of influencing viral binding. However, binding is not 
predictive of perinatal transmission, fusion, or replicative fitness. Viral entry into target 
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cells is a complicated process that is influenced by multiple factors and it is likely that no 
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Figure 1. Relative binding of EGFP/DsRed2 labeled viruses.  Binding of viruses 
containing the patient Env V1-V5 with EGFP/DsRed2 was done in U87-derived cells. 
One day prior to the assay U87 and U87.CD4.CCR5 cells were plated, virus was added 
the next day next day and incubated for 1hr at 4ºC. Cells were vigorously washed with 
PBS, lysed, and collected. Lysates were clarified by centrifuging at 10,000xg for 10min 
and assayed for bound p24 by p24 ELISA as described above. Relative binding is 
determined using the U87 cell line to measure background signal (non-specific binding) 
and expressed as a fold increase over this level. A. Relative binding of infant (EGFP) and 
mother (DsRed2) clones from MIP 1084. B. Average binding of all infant and mother 
clones. 
Figure 2. Relative binding of viruses from MIP 1084.  Binding of viruses containing 
the patient Env V1-V5 was done in U87-derived cells. One day prior to the assay U87 
and U87.CD4.CCR5 cells were plated, virus was added the next day next day and 
incubated for 1hr at 4ºC. Cells were vigorously washed with PBS, lysed, and collected. 
Lysates were clarified by centrifuging at 10,000xg for 10min and assayed for bound p24 
by p24 ELISA as described above. Relative binding is determined using the U87 cell line 
to measure background signal (non-specific binding) and expressed as a fold increase 
over this level. A. Relative binding of infant (EGFP) and mother (DsRed2) clones from 
MIP 1084. B. Average binding of all infant and mother clones. 
Figure 3. Percent binding and fusion of MIP-derived viruses. Both binding and fusion 
were done in SupT1-CCR5 cells as described previously. A-C. Percent Binding. Binding 
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is calculated as the percentage of input virus that was bound to the cells. D-F. Percent 
Fusion. Fusion is calculated as the percent of cells with BlaM activity. 
Figure 4. Binding and fusion of infant versus mother viruses. A. Comparison of 
binding in infant ( ) and mother ( ) variants with patient-derived V1-V5 for each 
transmission pair. Average binding is noted with the black bar. B. Comparison of fusion 
in infant ( ) and mother ( ) variants with patient-derived V1-V5 for each transmission 












































































































MIP R R2 
2669 0.424 0.180 
2617 0.192 0.037 
1084 0.027 0.0007 
Table 1. Correlation 
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 Our previous study demonstrated that replicative fitness, influenced by the Env 
V1-V5 region derived from subtype C transmitting MIP, is predictive of transmission. 
Replicative fitness was higher in transmitted infant-derived viruses than non-transmitted 
mother-derived viruses. However, no other biological properties of Env that have been 
measured are predictive of replicative fitness or perinatal transmission. The current study 
sought to determine if fusion and binding activities are influenced by Env V1-V5 and if 
any differences correlate to replicative fitness and transmission. We found that neither 
fusion nor binding is predictive of transmission. However, we did see clonal variation in 
both fusion and binding activities of all MIP Clones studied, demonstrating that Env V1-
V5 is capable of influencing both activities.   
 Differences that we observed in fusion of the viral variants from the MIP did not 
correlate with transmission, but did correlate with infectivity. We also saw that the 
amount of Env incorporated into virions cannot account for differences in fusion 
activities. It is likely that the primary genetic sequence of the Env from the MIP, the 
structure/stability of the Env from the MIP, or a combination of both factors may play a 
role in fusion mediated viral entry into target cells. We also found that fusion and binding 
did not correlate, which provides further evidence that entry occurs in distinct stages that 
are influenced by different viral and cellular factors.  
 There are some limitations with our study. The assay we used to measure viral 
binding was not yet optimized and additional binding assays should be employed to 
confirm these results. There are also a number of follow-up analyses that need to be 
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carried out. First, in depth analysis of the Env sequences from the MIP clones should be 
performed. Mutagenesis analysis should also be done to determine if any mutations are 
capable of influencing either fusion or binding or both. Second, the location of PNGS 
should also be analyzed to determine if they are influencing fusion or binding. Third, the 
structural analysis should be done to determine the stability of the gp120-gp41 complex 
of the Env derived from the MIPs. Nevertheless, the data from this study have provided 
several avenues of new inquiry to better understand the functional properties of Env and 
its role in perinatal transmission. 
